Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Bitdeer Reports Unaudited Financial Results for the Second Quarter of 2026 (GlobeNewswire EN) +++ BITDEER Aktie -8,93%

WUXI BIOLOGICS Aktie

 >WUXI BIOLOGICS Aktienkurs 
5.12 EUR    +2.7%    (TradegateBSX)
Ask: 5.12 EUR / 684 Stück
Bid: 5.02 EUR / 699 Stück
Tagesumsatz: 2159 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
WUXI BIO Aktie über LYNX handeln
>WUXI BIOLOGICS Performance
1 Woche: +17,6%
1 Monat: +23,0%
3 Monate: +40,8%
6 Monate: +23,7%
1 Jahr: +56,2%
laufendes Jahr: +43,1%
>WUXI BIOLOGICS Aktie
Name:  WUXI BIOLOGICS-0,0000083
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  KYG970081173 / A2QJCN
Symbol/ Ticker:  1FW2 (Frankfurt)
Kürzel:  FRA:1FW2, ETR:1FW2, 1FW2:GR
Index:  -
Profil:  Wuxi Biologics (Cayman) Inc. is a major player in the biotechnology and medical research sector, specializing in providing comprehensive solutions for the discovery, development, and manufacturing of biologic drugs. As an investment holding company, ..
>Volltext..
Marktkapitalisierung:  20958.59 Mio. EUR
Unternehmenswert:  20127.81 Mio. EUR
Umsatz:  2628.41 Mio. EUR
EBITDA:  1012.28 Mio. EUR
Nettogewinn:  591.84 Mio. EUR
Gewinn je Aktie:  0.14 EUR
Schulden:  384.25 Mio. EUR
Liquide Mittel:  1141.09 Mio. EUR
Operativer Cashflow:  797.94 Mio. EUR
Bargeldquote:  1.89
Umsatzwachstum:  2.77%
Gewinnwachstum:  28.77%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel -
Suchwörter:  WUXI BIOLOGICS, WUXI BIO
Letzte Datenerhebung:  10.08.26
>WUXI BIO Kennzahlen
Aktien/ Unternehmen:
Aktien: 4144.99 Mio. St.
Frei handelbar: 89.77%
Leerverk. Aktien: -
Rückkaufquote: 0.13%
Mitarbeiter: 13252
Umsatz/Mitarb.: 0.2 Mio. EUR
Analysten:
Analystenrating: Buy
Kursziel: 7.72%
Bewertung:
KGV: 36.16
KGV lG: 30.62
KUV: 6.98
KBV: 3.58
PEG-Ratio: 0.67
EV/EBITDA: 19.88
Rentabilität:
Bruttomarge: 46.01%
Gewinnmarge: 22.52%
Operative Marge: 30.53%
Managementeffizenz:
Gesamtkaprendite: 8.09%
Eigenkaprendite: 10.97%
>WUXI BIO Peer Group
Gesundheit, Antikörper- Behandlung
 
10.08.26 - 10:30
Full-day Takeaway: HSI Up 269 pts; HSTI Up 61 pts; LAOPU GOLD Up over 12%; LENOVO GROUP, WUXI APPTEC, TECHTRONIC IND, WUXI BIO, GENSCRIPT BIO Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 269 pts or 1.0% to 25,937. HSTI rose 61 pts or 1.3% to 4,919. HSCEI gained 90 pts or 1.1% to 8,621. Market turnover reached $240.28 billion.Active Heavyweights:BABA (09988.HK) closed at $126.7, up 2.3%XIAOMI (01810.HK) closed at $27.62, up 2.1%TENCENT (00700.HK) closed at $481.4, up 0.5%HSI & HSCEI Constituent......
10.08.26 - 06:15
Midday Takeaway: HSI Closes Midday at 25,853, Up 185 pts; HSTI Closes Midday at 4,876, Up 17 pts; LAOPU GOLD Up over 8%; WUXI APPTEC, WUXI BIO, TECHTRONIC IND, GENSCRIPT BIO, SITC Hit New Highs (AAStocks)
 
At midday close, HSI rose 185 pts or 0.7% to 25,853. HSTI rose 17 pts or 0.4% to 4,876. HSCEI gained 56 pts or 0.7% to 8,587.Active Heavyweights:BABA (09988.HK) closed at $126.4, up 2.1%XIAOMI (01810.HK) closed at $27.3, up 0.9%TENCENT (00700.HK) closed at $478.4, down 0.1%HSI & HSCEI Constituents on Move:LAOPU GOLD (06181.HK) c......
07.08.26 - 10:30
Full-day Takeaway: HSI Closes at 25,668, Up 137 pts; HSTI Closes at 4,858, Up 37 pts; WUXI BIO Up over 10%; WUXI BIO, LENOVO GROUP, WUXI APPTEC, GENSCRIPT BIO, PACIFIC BASIN Hit New Highs; Market Turnover Rises (AAStocks)
 
At close, HSI rose 137 pts or 0.5% to 25,668. HSTI rose 37 pts or 0.8% to 4,858. HSCEI gained 32 pts or 0.4% to 8,531. Market turnover reached $259.69 billion.Active Heavyweights:XIAOMI (01810.HK) closed at $27.06, up 0.7%BABA (09988.HK) closed at $123.8, down 0.5%TENCENT (00700.HK) closed at $478.8, down 0.1%HSI & HSCEI Constit......
07.08.26 - 06:30
Midday Takeaway: HSI Closes Midday at 25,567, Up 37 pts; HSTI Closes Midday at 4,837, Up 16 pts; WUXI BIO Up over 6%; WUXI BIO, WUXI APPTEC, PACIFIC BASIN, SWIRE PACIFIC B, GENSCRIPT BIO Hit New Highs (AAStocks)
 
At midday close, HSI rose 37 pts or 0.1% to 25,567. HSTI rose 16 pts or 0.3% to 4,837. HSCEI gained 5 pts or 0.1% to 8,503.Active Heavyweights:XIAOMI (01810.HK) closed at $26.72, down 0.5%BABA (09988.HK) closed at $123.9, down 0.4%MEITUAN (03690.HK) closed at $92.45, up 0.3%TENCENT (00700.HK) closed at $478.6, down 0.1%HSI & HSC......
29.07.26 - 04:33
WuXi Biologics Recognized by FTSE4Good for the Sixth Consecutive Year, Underscoring Value Creation Through Green CRDMO (PR Newswire)
 
SHANGHAI, July 28, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been included in the FTSE4Good Index Series in recognition of its outstanding sustainability performance,......
09.07.26 - 09:33
WuXi Biologics′ MFG8 Drug Substance Facility Secures FDA PLI Approval, Advancing Commercial Supply of a Potential Blockbuster Autoimmune Therapy (PR Newswire)
 
SHIJIAZHUANG, China, July 9, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG8 drug substance manufacturing facility located in Hebei has successfully passed the Pre-License......
08.07.26 - 09:18
WuXi Biologics Achieves MSCI ESG AAA Rating and MSCI Selection Indexes Inclusion for Fourth Consecutive Year (PR Newswire)
 
Maintained the highest MSCI AAA ESG Rating for the fourth consecutive year under the new ESG Model 5.0 (2026) Included in the MSCI ESG Selection Indexes for the fourth consecutive year Leader in Green CRDMO solutions for a healthier future SHANGHAI, July 8, 2026 /PRNewswire/ -- WuXi......
03.07.26 - 06:00
Research: UBS Raises WUXI BIO TP to HKD51.1, Strong Demand Momentum Continues (AAStocks)
 
UBS published a report stating that it hosted a healthcare virtual roadshow meeting for WUXI BIO (02269.HK). Management reiterated its guidance for 2026 revenue growth of 13% to 17% YoY (16% to 20% excluding foreign exchange impact). Despite ongoing foreign exchange pressure, this reflects management's confidence in underlying d......
30.06.26 - 07:51
WuXi Biologics Receives Brazil ANVISA GMP Certification to Enable Global Commercial Manufacturing of Innovative Cancer Immunotherapy (PR Newswire)
 
WUXI, China, June 30, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that two of its manufacturing facilities in Wuxi — Drug Substance Facility 2 (MFG2) and Drug Product Facility 1 (DP1) —......
24.06.26 - 08:42
WuXi Biologics′ 25th Drug Substance Facility Completes First GMP Production, Manufacturing Process Execution with Zero Deviations (PR Newswire)
 
SHANGHAI, June 24, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its MFG17 drug substance facility located at the Shanghai Fengxian site has successfully completed its first GMP......
24.06.26 - 05:15
WUXI BIO, WUXI APPTEC Jump Up ~6%, 9%; Citi Says CN Healthcare Sector Valuations Attractive with Good Entry Point (AAStocks)
 
WUXI BIO (02269.HK) opened 1.16% higher today (24th) and once peaked at HKD33.44. It last stood at HKD32.98, up 5.91%, with 18.0207 million shares traded, involving HKD589 million.WUXI APPTEC (02359.HK) opened 0.38% higher and once peaked at HKD143.5. It last posted at HKD142.2, up 8.72%, with 5.6117 million shares traded, invol......
18.06.26 - 07:00
WuXi Biologics′ Suzhou Biosafety Testing Center Received Fourth EMA GMP Certification, Enabling 19 Commercial Products for the European Market (PR Newswire)
 
SUZHOU, China, June 18, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that its Biosafety Testing Center in Suzhou has successfully passed a Good Manufacturing Practice (GMP) inspection by......
10.06.26 - 04:00
H Shrs: HSI Opens Down 123 pts; HSBC HOLDINGS Down 2%+; WUXI BIO Slumps ~5% (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
10.06.26 - 04:00
WUXI BIO Spends HKD74.88M to Repurchase 2.522M Shares (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
09.06.26 - 03:45
WUXI BIO Repurchased 6.537M Shares Yesterday Involving Nearly HKD200 Million (AAStocks)
 
WUXI BIO (02269.HK) repurchased 6.537 million shares on the Stock Exchange yesterday (8th), at prices ranging from HKD30.26 to HKD31.7 per share, involving nearly HKD200 million.Since the share repurchase mandate was approved (6 June 2025), the Group has cumulatively repurchased 41.754 million shares, representing 1.02623% of it......
08.06.26 - 10:12
WuXi Biologics Ireland Wins Top Honors at the 2026 Life Sciences Industry Awards (PR Newswire)
 
DUNDALK, Ireland, June 8, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its Ireland site won the "Overall Excellence in Life Sciences" award, the highest recognition at the 2026......
08.06.26 - 06:30
HSBC Research Raises WUXI BIO TP to HKD45.8, Maintains Buy Rating (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
05.06.26 - 04:48
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility (PR Newswire)
 
SINGAPORE, June 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has completed the topping out of the Drug Product (DP) facility at its Singapore CRDMO Hub (Hub). Once operational,......
03.06.26 - 04:36
WuXi Biologics Named to CDP Supplier Engagement Assessment A List for the Second Consecutive Year (PR Newswire)
 
SHANGHAI, June 2, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has been named to the CDP Supplier Engagement Assessment (SEA) A List for the second consecutive year. The......
01.06.26 - 05:00
WUXI BIO Up 5% as Nomura Says Reiterated Full-yr Revenue Growth Guidance and Buyback Are Positive Signals of Undervaluation (AAStocks)
 
WUXI BIO (02269.HK) opened 1.08% higher today (1st) and once soared 6.4% in early trading to a peak of HKD35.46. It last traded at HKD35.02, up 5.04%, with 18.7564 million shares traded, involving HKD658 million.Nomura believed that, together with the plan announced earlier this week to repurchase up to 407 million shares for no......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Überalterung ist vor allem ein Problem der leitenden Gremien. - Dr. Gerhard Kocher
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!